Cotización Biogen - 1BIIB

Herramientas de nivel profesional para inversores individuales.

Premium

Último Precio

138.65

Postura de Compra

138.60

Postura de Venta

139.65

Volume Operado de la Acción

138.65 Rango del Día 139.80

133.30 Rango de 52 semanas 229.20

Capitalización de Mercado [m]

20.204B

Precio Anterior

139.10

Precio de Apertura

139.80

Hora

138.65

Última hora de negociación

06:16:36

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

Acciones en circulación

145,719,340

Rendimiento del Dividendo

Ratio Precio/Utilidad

18.06

Beneficio por acción (BPA)

7.97

turnover

9.84B

Beneficio neto

1.16B

Sector

Biological Pds,ex Diagnstics

Industria

Biological Pds,ex Diagnstics

Sitio web

www.biogen.com

Sede

Wilmington, Delaware, USA

Fundado

Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the Italian Stock Exchange with ticker 1BIIB. The last closing price for Biogen was 139.10 €. Over the last year, Biogen shares have traded in a share price range of 133.30 € to 229.20 €.

Biogen currently has 145,719,340 shares in issue. The market capitalisation of Biogen is 20.27 € billion. Biogen has a price to earnings ratio (PE ratio) of 18.06.

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo...

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Once every four weeks maintenance dosing may be easier for patients and care partners to...

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher...

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease LEQEMBI is the only FDA-approved anti-amyloid...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity Dapirolizumab pegol (DZP) met its...

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd...

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference -New testing method highlights link...

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases The collaboration aims to...

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as...

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 Robin Kramer, Chief Accounting Officer, to Succeed HimCAMBRIDGE, Mass., Oct. 28, 2024 (GLOBE...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-1.7	-1.21125757036	140.35	141.7	138.5	38	139.52578947	DE
4	-8.05	-5.48738922972	146.7	146.7	133.3	54	138.59941657	DE
12	-24.3	-14.9125498619	162.95	162.95	133.3	56	145.76782511	DE
26	-47.25	-25.4168908015	185.9	189.25	133.3	51	156.58722628	DE
52	-85.55	-38.1578947368	224.2	229.2	133.3	43	174.51357068	DE
156	-76.95	-35.6910946197	215.6	244.6	133.3	39	177.34489341	DE
260	-76.95	-35.6910946197	215.6	244.6	133.3	39	177.34489341	DE

1BIIB - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Biogen?

El precio actual de las acciones de Biogen es 138.65 €

¿Cuántas acciones de Biogen están en circulación?

Biogen tiene 145,719,340 acciones en circulación

¿Cuál es la capitalización de mercado de Biogen?

La capitalización de mercado de Biogen es EUR 20.27B

¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Biogen?

Biogen ha negociado en un rango de 133.30 € a 229.20 € durante el último año

¿Cuál es el ratio PE (precio/beneficio) de Biogen?

El ratio precio/beneficio de Biogen es 18.06

¿Cuál es el ratio de efectivo a ventas de Biogen?

El ratio de efectivo a ventas de Biogen es 2.13

¿Cuál es la moneda de reporte de Biogen?

Biogen presenta sus resultados financieros en USD

¿Cuál es el último ingresos anual de Biogen?

El último ingresos anual de Biogen es USD 9.84B

¿Cuál es el último beneficio anual de Biogen?

El último beneficio anual de Biogen es USD 1.16B

¿Cuál es la dirección registrada de Biogen?

La dirección registrada de Biogen es 3411 SILVERSIDE ROAD TATNALL, BUILDING #104, NEW CASTLE, WILMINGTON, DELAWARE, 19810

¿Cuál es la dirección del sitio web de Biogen?

La dirección del sitio web de Biogen es www.biogen.com

¿En qué sector industrial opera Biogen?

Biogen opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
NTWNetweek SpA	0.088 € (18.92%)	1.14M
WIVN26iVision Tech SpA	0.4701 € (17.53%)	15.9k
IVNiVision Tech SpA	2.60 € (10.17%)	135k
PORPortobello SPA	2.22 € (9.90%)	23.4k
SFTSoftlab SPA	0.835 € (8.44%)	4.25k
WRDF25Redelfi SpA	1.25 € (-17.75%)	2k
WAMB26Ambromobiliare SpA	0.033 € (-17.29%)	10k
WTFINTrevi Finanziaria Industriale Spa	0.60 € (-16.67%)	8
CYBCyberoo SpA	1.485 € (-15.63%)	83.92k
WABTGAlfio Bardolla Training Group Spa	0.127 € (-15.33%)	39.01k
TITTelecom Italia SpA	0.2663 € (0.30%)	108.7M
ISPIntesa Sanpaolo Spa	4.1485 € (-1.06%)	31.46M
STLAMStellantis NV	12.11 € (-6.57%)	19.02M
FDAFidia	0.0152 € (-5.00%)	16.47M
SPMSaipem Spa	2.312 € (-2.41%)	16.13M